AVBP logo

AVBP
ArriVent BioPharma Inc.

138
Mkt Cap
$1.3B
Volume
63,699.00
52W High
$32.14
52W Low
$16.10
PE Ratio
-7.90
AVBP Fundamentals
Price
$27.17
Prev Close
$27.87
Open
$28.31
50D MA
$26.69
Beta
1.00
Avg. Volume
518,715.56
EPS (Annual)
-$4.32
P/B
3.90
Rev/Employee
$0.00
$461.06
Loading...
Loading...
News
all
press releases
ArriVent BioPharma (NASDAQ:AVBP) Upgraded at Truist Financial
Truist Financial upgraded ArriVent BioPharma to a "strong-buy" rating in a research note on Monday...
MarketBeat·13d ago
News Placeholder
More News
News Placeholder
ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Monday
ArriVent BioPharma (NASDAQ:AVBP) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-arrivent-biopharma-inc-stock...
MarketBeat·14d ago
News Placeholder
Noteworthy Thursday Option Activity: AVBP, VIAV, ASTS
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in ArriVent Biopharma Inc (Symbol: AVBP), where a total volume of 4,042 contracts has been traded thus far today, a contract volume which is representative of appro...
Nasdaq News: Markets·18d ago
News Placeholder
FY2026 Earnings Estimate for AVBP Issued By Lifesci Capital
ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Equities researchers at Lifesci Capital dropped their FY2026 earnings per share estimates for ArriVent BioPharma in a report released on Monday, April 27th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings of...
MarketBeat·18d ago
News Placeholder
Citigroup Increases ArriVent BioPharma (NASDAQ:AVBP) Price Target to $45.00
Citigroup increased their target price on shares of ArriVent BioPharma from $33.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday...
MarketBeat·24d ago
News Placeholder
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one...
MarketBeat·24d ago
News Placeholder
ArriVent BioPharma (NASDAQ:AVBP) Hits New 12-Month High - What's Next?
ArriVent BioPharma (NASDAQ:AVBP) Hits New 12-Month High - Here's Why...
MarketBeat·26d ago
News Placeholder
ArriVent BioPharma (NASDAQ:AVBP) Hits New 1-Year High - Time to Buy?
ArriVent BioPharma (NASDAQ:AVBP) Hits New 52-Week High - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·1mo ago
News Placeholder
Are Medical Stocks Lagging AstraZeneca (AZN) This Year?
Here is how Astrazeneca (AZN) and ArriVent BioPharma, Inc. (AVBP) have performed compared to their sector so far this year.
Zacks·1mo ago
<
1
2
...
>

Latest AVBP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.